Shanghai Upper Bio-Tech Pharma Co., Ltd.

Shanghai Upper Bio-tech Co., Ltd. is located in Zhangjiang Science City Modern Medical Device Park in Shanghai. Our company specializes in the development, production, sales, and big data services of internet-enabled intelligent point-of-care testing (iPOCT) products. Upper holds over 400 intellectual property rights and has participated in more than 20 national and provincial-level major projects. It has led the publication of three industry monographs, including POCT, iPOCT, and IVD +(Big Data Smart Diagnosis). Our company has received seven scientific and technological awards, 10+ honors such as National Key New Products and Shanghai High-Tech Achievement Transformation Projects, and contributed to five national, industrial, and group standards. Designated as a National Specialized and Sophisticated Small Giant Enterprise, a National Intellectual Property Demonstration Enterprise, and home to a Postdoctoral Research Workstation, Shanghai Engineering Technology Research Center for Point-of-Care Testing, and Shanghai Enterprise Technology Center, Upper is a leader in innovation. Focused on rapid quantitative testing for cardiovascular diseases, diabetes nephropathy, autoimmune disorders, reproductive health, infectious diseases, and inflammatory infections, Our company has launched over 60 instrument and reagent products. These are used in over 1,000 medical institutions nationwide and internationally, serving tens of millions of patients annually. Through publications and industry initiatives, Our company introduced the "iPOCT" concept centered on precision, automation, cloud-based services, and sharing, along with a "smart diagnosis + health big data" model. It also pioneered the "3D Innovation(Instrument + Reagent + AI)" strategy integrating instruments, reagents, and cloud quality control. Listed on the National Equities Exchange and Quotations (NEEQ) under the code 873758 and entering the Innovation Tier, Upper leverages Shanghai Free Trade Zone policies and Zhangjiang’s biopharmaceutical ecosystem. The company aims to accelerate synergies between capital, technology, and markets, establishing itself as a premier brand in China’s digital diagnostic sector while contributing to Shanghai’s and China’s strategic goals.